Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease

Here, we report the history of a 42-year-old female patient with sporadic mismatch-repair-deficient metastatic colorectal cancer and abdominal bulky disease, who received pembrolizumab (200 mg every 3 weeks) after the failure of third-line treatment. Restaging 3 months after initiation of treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Kieler, Markus, Scheithauer, Werner, Zielinski, Christoph C, Chott, Andreas, Al-Mukhtar, Ali, Prager, Gerald W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5174801/
https://www.ncbi.nlm.nih.gov/pubmed/28255450
http://dx.doi.org/10.1136/esmoopen-2016-000084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5174801/
https://www.ncbi.nlm.nih.gov/pubmed/28255450
http://dx.doi.org/10.1136/esmoopen-2016-000084

Ejemplares similares